Cleveland Clinic, working with Volcano (now Philips), helped create the industry-leading intravascular ultrasound (IVUS) product line for coronary plaque characterization. This technology uses advanced, proprietary spectral analysis techniques to classify plaque into four tissue types, with 93-97% accuracy.
The Regenerative Medicine Laboratory, led by George Muschler, MD, is using advanced imaging and robotic tools to create a novel platform for optimizing tissue-derived, colony-founding connective tissue progenitors. The work will advance the field of cell manufacturing, specifically the expansion of human mesenchymal stromal cells (MSCs), and will greatly improve the quality and reproducibility of MSC manufacturing and use in clinical therapies, drug development and research. Dr. Muschler was awarded $3.3 million from the National Institutes of Health to fund this innovative research.